This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Momenta Pharmaceuticals CEO Presents At 2012 Citi Global Health Care Conference (Transcript)

Stocks in this article: MNTA

Momenta Pharmaceuticals ( MNTA)

2012 Citi Global Health Care Conference

Feb 28, 2012 11:00 AM ET

Executives

Analyst

Presentation

Unidentified Company Representative

I'd like to draw your attention to our safe harbor statement and risk factors included in our SEC filings. Momenta Pharmaceuticals is using innovative characterization tools, methods for determining structure and process and applying patented methods and approaches to identifying the structure, the process and the biology for complex mixture drugs and we do that in order to develop a portfolio of both generic and novel products. So we are based in Cambridge, Massachusetts, approximately 200 employees, and our approach was validated with the approval and launch of a generic Lovenox in July of 2010. We reported $366 million of cash as of December 2011 and we have collaborations with Sandoz division of Novartis with generic Lovenox and generic Copaxone and recently signed six products Follow-On Biologics collaboration with Baxter.

So just to recap 2011, a very eventful year for us. Generic Lovenox generated over $1 billion in sales to Sandoz and for most of the year for the first three quarters of the year, we were earning a profit share on those sales and then earned royalty during most of the fourth quarter of 2011. Competitor generic Lovenox was approved in September of 2011. We managed to keep that product up in market temporarily to an injunction but that injunction was stayed in January of this year. We did sign a collaboration with Baxter in December; I'll talk more about that. They have paid in the first quarter, their $33 million upfront payment in connection with that collaboration.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,858.03 +30.28 0.17%
S&P 500 2,074.70 +1.87 0.09%
NASDAQ 4,796.2820 +8.9650 0.19%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs